Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals, a company that develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease, has commenced Optina Phase II clinical trial for the treatment of diabetic macular edema.
Subscribe to our email newsletter
Ampio Pharma claimed that Optina is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina to reduce diabetic macular edema in patients.
Ampio Pharma has tied up with St Michael’s Hospital in Toronto, Canada, as a final step for ethics board approval which is expected in the next few days.
Don Wingerter, CEO of Ampio Pharma, said: “We are very excited to be commencing this trial and pending the final approval of the ethics board we will commence patient recruitment in the next weeks.”
David Bar-Or, chief scientific officer of Ampio Pharma, said: “After accumulating in-vitro and animal data, it is gratifying to begin treating patients for this debilitating disease.”